Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

NCT01703286 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo
DRUG: Linagliptin
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: Glimepiride

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]